Sanofi
Intertwining ribbons of blue and purple light flowing across a gradient background.

We are committed to ensuring the medicines we deliver are accessible and affordable for those who need them.

We are committed to ensuring the medicines we deliver are accessible and affordable for those who need them.

Our Pricing Principles & Perspectives

Prescription Medicine Pricing: Advancing Responsible Leadership

At Sanofi, we have a longstanding commitment to fostering healthcare systems that make our treatments accessible and affordable to those in need. 

Our Pricing Principles detail how we price our medicines and advocate for policy solutions to make the system work better for patients and their care teams. By publishing results over the past decade, we aim to build transparency and enable a more informed U.S. dialogue on medicine pricing.

The Three Pillars of Our Pricing Principles

Clear Rationale for Pricing:

We take a holistic approach to pricing new medicines, considering patient perspectives, clinical value compared to existing treatments, economic impact on overall healthcare costs, social contributions to quality of life, and system-wide affordability.

Reporting of U.S. Pricing Actions:

We balance innovation and responsibility to help contain healthcare spending. We adhere to responsible pricing principles for list price adjustments and annually disclose any mandatory supplemental rebates triggered by those actions.

Continued Transparency in the U.S.:

We annually disclose our average aggregate U.S. list and net price changes to foster better-informed discussions about patient access and affordability.

Featured Brief

NEW Prior Authorization: How Targeted Reforms Can Protect Patient Access

Prior authorization is recognized as one of the biggest burdens for patients when it comes to accessing tests, treatments, or medications. Targeted reforms can protect patient access.

Our Perspectives on Proposed Policy Solutions

Two people at a medical reception desk with a computer and cross symbol.

NEW Step Therapy: How “Fail First” Can Fail Patients

An illustration of two Sanofi scientists holding a silhouetted head made of four different puzzle pieces.

Unlocking New Potential for Existing Medicines

Giant question mark and green speech bubble with three illustrated figures in the foreground.

A Closer Look at 340B

An African American female speaks to a white male medical professional on the phone.

Navigating the Complexities of Accessing Specialty Medicine

A female medical professional shows a tablet device to two patients sitting on a couch.

Health Policy Solutions Protecting Innovation

Explore more

A female doctor with blond hair faces a male Sanofi employee at a table having a consultation

Patient Support

A patient speaks to a pharmacist at the pharmacy counter. A title reads: Utilization Management: Roadblocks for Patients.

June 29, 2026

Putting Patients First by Reining In Prior Authorization and Step Therapy

Illustration of a team meeting: five people sit around a conference table while one person stands and presents a pie chart on a screen.

March 3, 2026

Navigating U.S. Policy: How Data and Transparency Guide Our Efforts

A stainless steel machine with a conveyor belt moves hundreds of purple pills along a Sanofi manufacturing line.

November 22, 2024

Sanofi Tackles 340B Abuse with Innovative Credit Model

MAT-US-2017357-v12.0-06/2026